The maker of medical devices posted third-quarter results that broadly met analyst expectations. That wasn't the reason for the resulting investor sell-off, however.

Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.

Edwards Lifesciences Corporation (NYSE:EW ) Q3 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Mark Wilterding - SVP, IR and Treasurer Bernard Zovighian - CEO Scott U...

Edwards Lifesciences (EW) came out with quarterly earnings of $0.59 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.61 per share a year ago.

Edwards Lifesciences Corp on Wednesday reported a 12% rise in third-quarter sales, helped by strong demand for the company's artificial heart valves and other devices.

We have narrowed our search to five large-cap stocks that are set to declare third-quarter earnings results this week. These are: EW, VICI, VMC, GLPI, MBLY.

Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.

Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors remain optimistic about Edward Lifesciences (EW) on the strength of the Critical Care business and TAVR sales.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW). But which of these two stocks presents investors with the...

Investors still have concerns about a potential recession despite a steady decline in the inflation rate in response to the Fed's aggressive rate hike plan.

IRVINE, Calif., Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, Septe...

Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.

Edwards Lifesciences is the global leader in medical devices for structural heart disease and critical care monitoring. Their Transcatheter Aortic Valve Replacement technology dominates the market ...